nanobiotix

Previously, Dr. Borghi worked in the RD oncology department for Sanofi-Aventis, one of the five largest pharmaceutical companies in the world, until the onset of 2008, when she joined Nanobiotix. She has lead successful clinical trials worldwide for major drugs and registration in the Oncology field. Dr. Borghi began working in the pharmaceutical industry in 1996 on drug safety and international reporting, mainly for oncology and cardiovascular drugs.  She began working on pivotal cancer clinical trials in 1999, including early colon cancer, early- and late-stage breast cancer, and prostate cancer, for which she was responsible for a chemotherapy product registration.

In addition, Dr. Borghi has worked on soft tissue sarcoma, lung cancer and phase I studies for chemotherapies, antisense and targeted therapies.  Most of her recent work was focused on tumor perfusion modifiers such as antivascular agents.
Dr. Borghi obtained her medical degree from the University of Cordoba School of Medicine in March 1984 and the French equivalent in 1994 from the University of Paris V.